Drug intelligence / Profile preview

CNP-Arg-PTX

Development stage: Preclinical
Lead developer: SiNON Nano Sciences
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules

Overview

**CNP-Arg-PTX** is a preclinical paclitaxel nanomedicine developed by SiNON Nano Sciences for cancer, including brain-directed oncology applications. It encapsulates **paclitaxel** in a carbon nanoparticle carrier functionalized with arginine, with the delivery system intended to improve transport across the blood-brain barrier, tumor-directed delivery, drug stability, and controlled release. The therapeutic cytotoxic activity is expected to derive from paclitaxel-mediated stabilization of microtubules and disruption of mitosis.

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on CNP-Arg-PTX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CNP-Arg-PTX.

Explore the full profile